Cardiovascular Disease

Core Summary The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Mounjaro (tirzepatide) for reducing cardiovascular risk, marking a major expansion of GLP-1 drug indications. Previously used primarily for treating type 2 diabetes and obesity, the drug is now proven to significantly reduce the risk of heart attacks and strokes. This decision places Mounjaro in direct competition with Novo Nordisk’s Ozempic in the cardiovascular protection space, signaling a new phase in metabolic disease treatment. ...

Researchers from the University of Barcelona and University of Oregon develop a novel DNA-based cholesterol therapy that reduced LDL cholesterol by 47% in animal models, without statin-related side effects.